OpenURL Connection Search

Select item for more details and to access through your institution.

Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study.
Published in:
Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 1, p. 60, doi. 10.1111/apt.17525
By:
- Casanova, María José;
- Nantes, Óscar;
- Varela, Pilar;
- Vela‐González, Milagros;
- Rivero, Montserrat;
- Sierra‐Gabarda, Olivia;
- Riestra, Sabino;
- Barreiro‐de Acosta, Manuel;
- Martín‐Rodríguez, María del Mar;
- Gargallo‐Puyuelo, Carla Jerusalén;
- Reygosa, Cristina;
- Muñoz, Roser;
- de la Filia‐Molina, Irene García;
- Núñez‐Ortiz, Andrea;
- Kolle, Lilyan;
- Calafat, Margalida;
- Huguet, José María;
- Iglesias‐Flores, Eva;
- Martínez‐Pérez, Teresa de Jesús;
- Bosch, Orencio
Publication type:
Article
Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study.
Published in:
Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 12, p. 1277, doi. 10.1111/apt.16361
By:
- Casanova, María José;
- Chaparro, María;
- Nantes, Óscar;
- Benítez, José Manuel;
- Rojas‐Feria, María;
- Castro‐Poceiro, Jesús;
- Huguet, José María;
- Martín‐Cardona, Albert;
- Aicart‐Ramos, Marta;
- Tosca, Joan;
- Martín‐Rodríguez, María del Mar;
- González‐Muñoza, Carlos;
- Mañosa, Miriam;
- Leo‐Carnerero, Eduardo;
- Lamuela‐Calvo, Luis Javier;
- Pérez‐Martínez, Isabel;
- Bujanda, Luis;
- Hinojosa, Joaquín;
- Pajares, Ramón;
- Argüelles‐Arias, Federico
Publication type:
Article

Found: 2

Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study.

Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study.